Invega Information

INVEGA combines: The active metabolite of RISPERDAL® (risperidone) Innovative OROS® extended-release technology INVEGA demonstrated: Significant efficacy in the positive and negative symptoms of schizophrenia, Low weight gain and EPS rates comparable with placebo at the recommended 6-mg dose Total EPS-related adverse events at the 9-mg and 12-mg doses were 25, and 26,, respectively (versus 11, for placebo) The proportion of subjects having a weight gain of 7, body weight were comparable with placebo (5,) for 3 mg (7,) and 6 mg (6,). a higher incidence was seen for 9 mg (9,) and 12 mg (9,) Extensively studied in: 1665 patients with moderate to severe schizophrenia INVEGA,easy convenient dosing: Less than 10, of the dose is metabolized by any of the 4 identified metabolic pathways Not expected to cause clinically important interactions with drugs metabolized by the CYP450 pathway No dose adjustments for patients with mild to moderate hepatic impairment The short-term efficacy of INVEGA (3 to 15 mg once daily) was established in three placebo-controlled and active-controlled (olanzapine), 6-week, fixed-dose trials in non-elderly adult subjects (mean age of 37) who met DSM-IV criteria for schizophrenia: INVEGA delivered a full range of symptom control INVEGA offered an incidence of weight gain similar to that for placebo INVEGA delivered discontinuation rates due to adverse events that are similar to those for placebo across all doses Please see Product Details. Please see the full US Prescribing Information.